PGRN has potential therapeutic activity in neurodegenerative diseases since it has been found that viral vector gene delivery of GRN suppresses the development of disease-like phenotypes in murine models of Parkinson’s disease (PD) [2] and Alzheimer’s disease [3]. The gene discussed is GRN; the disease is early-onset autosomal dominant Alzheimer disease.